This is a preview of subscription content, log in via an institution to check access.
Reference
Borghi C, et al. Zofenopril is a cost-effective treatment for patients with left ventricular systolic dysfunction following acute myocardial infarction: a pharmacoeconomic analysis of the SMILE-4 study. ESC Congress 2013: Annual Congress of the European Society of Cardiology : abstr. P3293, 31 Aug 2013.
Additional information
* Survival of Myocardial Infarction Long-term Evaluation 4 Study
Rights and permissions
About this article
Cite this article
ICER of zofenopril in SMILE-4: a happy result. PharmacoEcon Outcomes News 688, 6 (2013). https://doi.org/10.1007/s40274-013-0755-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0755-1